

=> d his

(FILE 'HOME' ENTERED AT 14:43:00 ON 27 FEB 2008)

FILE 'CAPLUS' ENTERED AT 14:44:07 ON 27 FEB 2008

E US2005-532297/APPS

L1 1 S E3

FILE 'REGISTRY' ENTERED AT 14:47:07 ON 27 FEB 2008

FILE 'CAPLUS' ENTERED AT 14:47:15 ON 27 FEB 2008

L2 TRA L1 1- RN : 14 TERMS

FILE 'REGISTRY' ENTERED AT 14:47:15 ON 27 FEB 2008

L3 14 SEA L2

E "BENZAMIDE, 4-((4-METHYL-1-PIPERAZINYLMETHYL)-N-(4-METHYL-3-

E "BENZENESULFONAMIDE, 4-(1,1-DIMETHYLETHYL)-N-[6-(2-HYDROXYETH

E "BENZENESULFONAMIDE, 4-(1,1-DIMETHYLETHYL)-N-(6-(2-HYDROXYETH

L4 1 S "BENZAMIDE, 4-((4-METHYL-1-PIPERAZINYLMETHYL)-N-(4-METHYL-3-

L5 1 S "BENZENESULFONAMIDE, 4-(1,1-DIMETHYLETHYL)-N-(6-(2-HYDROXYETH

E "BENZAMIDE, 4-[(4-METHYL-1-PIPERAZINYLMETHYL)-N-[4-METHYL-3-

E "BENZAMIDE, 4-((4-METHYL-1-PIPERAZINYLMETHYL)-N-(4-METHYL-3-

E "BENZAMIDE, 4-((4-METHYL-1-PIPERAZINYLMETHYL)-N-(4-METHYL-3-

FILE 'STNGUIDE' ENTERED AT 14:57:11 ON 27 FEB 2008

FILE 'CAPLUS, USPATFULL, USPATOLD, USPAT2' ENTERED AT 15:12:34 ON 27 FEB 2008

L6 1520 S L4

L7 0 S PULMONARY HYHYPERTENSION

E PULMONARY HYPERTENSION

L8 10029 S PULMONARY HYPERTENSION

L9 9 S L6 AND L8

L10 2 S L9 AND (L6 (L) L8)

L11 7 S L9 NOT L10

L12 0 S L11 AND PD<2003

02/27/2008

L10 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:204044 CAPLUS <<LOGINID::20080227>>
DOCUMENT NUMBER: 146:226255
TITLE: Therapeutical Effect of Imatinib (STI571), a
Protein-Tyrosine Kinase Inhibitor in the Monocrotaline
Rat Model of Pulmonary Hypertension
AUTHOR(S): Dony, Eva Maria Marlene
CORPORATE SOURCE: Germany
SOURCE: (2006) No pp. Avail.: Metadata on Internet Documents,
Order No. 367520
From: Metadata Internet Doc. [Ger. Diss.] 2006,
(D0220-3), No pp. given
URL: <http://www.meind.de/search.py?recid=367520>
DOCUMENT TYPE: Dissertation
LANGUAGE: German
TI Therapeutical Effect of Imatinib (STI571), a Protein-Tyrosine Kinase
Inhibitor in the Monocrotaline Rat Model of Pulmonary
Hypertension
ST pulmonary hypertension imatinib STI571 therapeutic
therapy
IT Hypertension
(pulmonary; therapeutic effect of imatinib (STI571) as protein-tyrosine
kinase inhibitor in monocrotaline rat model of pulmonary
hypertension)
IT Disease models
Rattus
Therapy
(therapeutic effect of imatinib (STI571) as protein-tyrosine kinase
inhibitor in monocrotaline rat model of pulmonary
hypertension)
IT 152459-95-5, Imatinib 220127-57-1, STI571
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(therapeutic effect of imatinib (STI571) as protein-tyrosine kinase
inhibitor in monocrotaline rat model of pulmonary
hypertension)

L10 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:368928 CAPLUS <<LOGINID::20080227>>
DOCUMENT NUMBER: 140:368686
TITLE: Use of N-[5-(4-(4-methylpiperazinomethyl)benzoylamido)-
2-methylphenyl]-4-(3-pyridyl)-2-pyrimidineamine for
the treatment of pulmonary
hypertension
INVENTOR(S): Lasky, Joseph Alexander
PATENT ASSIGNEE(S): The Administrators of the Tulane Educational Fund, USA
SOURCE: PCT Int. Appl., 16 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

WO 2004037261 A1 20040506 WO 2003-IB4671 20031020
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT,
LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PG, PH, PL, PT, RO,
RU, SC, SE, SG, SK, SY, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN,
YU, ZA, ZW
RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE,
SI, SK, TR
AU 2003272007 A1 20040513 AU 2003-272007 20031020
JP 2006505582 T 20060216 JP 2004-546290 20031020
US 2006154936 A1 20060713 US 2005-532297 20050824
PRIORITY APPLN. INFO.: US 2002-421318P P 20021025
WO 2003-IB4671 W 20031020
REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT
TI Use of N-[5-(4-(4-methylpiperazinomethyl)benzoylamido)-2-methylphenyl]-4-
(3-pyridyl)-2-pyrimidineamine for the treatment of pulmonary
hypertension
AB . . . the use of I, or a pharmaceutically acceptable salt thereof, for
the manufacture of a medicament for the treatment of pulmonary
hypertension.
ST pyrimidineamine deriv pulmonary hypertension treatment
IT Prostaglandins
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(I; pyrimidineamine derivative for treatment of pulmonary
hypertension, and use with other agents)
IT Endothelin receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(blockers; pyrimidineamine derivative for treatment of pulmonary
hypertension, and use with other agents)
IT Drug delivery systems
(capsules; pyrimidineamine derivative for treatment of pulmonary
hypertension, and use with other agents)
IT Hypoxia
(pulmonary hypertension induced by; pyrimidineamine
derivative for treatment of pulmonary hypertension, and
use with other agents)
IT Hypertension
(pulmonary; pyrimidineamine derivative for treatment of pulmonary
hypertension)
IT Antihypertensives
Human
(pyrimidineamine derivative for treatment of pulmonary
hypertension)
IT Anticoagulants
Calcium channel blockers
Diuretics
(pyrimidineamine derivative for treatment of pulmonary
hypertension, and use with other agents)
IT 10102-43-9, Nitric oxide, biological studies
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(inhaled; pyrimidineamine derivative for treatment of pulmonary

hypertension, and use with other agents)


IT 9015-82-1, Angiotensin-converting enzyme 9025-82-5, Phosphodiesterase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; pyrimidineamine derivative for treatment of pulmonary
hypertension, and use with other agents)

IT 152459-95-5 220127-57-1
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(pyrimidineamine derivative for treatment of pulmonary
hypertension)

IT 51-41-2, Norepinephrine 58-61-7, Adenosine, biological studies
81-81-2, Warfarin 20830-75-5, Digoxin 21829-25-4, Nifedipine
42399-41-7, Diltiazem 75847-73-3, Enalapril 147536-97-8, Bosentan
171599-83-0, Viagra
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(pyrimidineamine derivative for treatment of pulmonary
hypertension, and use with other agents)

=> d 14

L4 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2008 ACS on STN
RN 152459-95-5 REGISTRY
ED Entered STN: 25 Jan 1994
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)
OTHER NAMES:
CN 4-(4-Methylpiperazin-1-ylmethyl)-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide
CN CGP 57148
CN Imatinib
MF C29 H31 N7 O
CI COM
SR CA
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CHEMCATS, CIN, DDFU, DRUGU, EMBASE, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*, PATDPASPC, PROMT, PROUSDDR, PS, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1278 REFERENCES IN FILE CA (1907 TO DATE)
22 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1296 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> d ibib

L1 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2004:368928 CAPLUS <<LOGINID::20080227>>
 DOCUMENT NUMBER: 140:368686
 TITLE: Use of N-[5-(4-(4-methylpiperazinomethyl)benzoylamido)-
 2-methylphenyl]-4-(3-pyridyl)-2-pyrimidineamine for
 the treatment of pulmonary hypertension
 INVENTOR(S): Lasky, Joseph Alexander
 PATENT ASSIGNEE(S): The Administrators of the Tulane Educational Fund, USA
 SOURCE: PCT Int. Appl., 16 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004037261	A1	20040506	WO 2003-IB4671	20031020
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SY, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR				
AU 2003272007	A1	20040513	AU 2003-272007	20031020
JP 2006505582	T	20060216	JP 2004-546290	20031020
US 2006154936	A1	20060713	US 2005-532297	20050824 <--
PRIORITY APPLN. INFO.:			US 2002-421318P	P 20021025
			WO 2003-IB4671	W 20031020
REFERENCE COUNT:	6	THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT		